3 recruiting, 2 active not recruiting. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Active not recruiting 2 |
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
Follow TNBC: new trials by email Literature Review of TNBC trials Research Report on TNBC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
| HS-10502 Combination Treatment in Patients With Advanced Solid Tumors HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib - Recurrent Ovarian Cancer, HER2-negative | Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 157 | 2025-05-07 | 2025-06-24 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors Enzelkitug, Atezolizumab, Pembrolizumab - Locally Advanced or Metastatic Solid Tumors, NSCLC | Phase 1 | Active not recruiting | Genentech, Inc. | 165 | 2022-10-20 | 2026-11-03 |
| A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC PM8002, nab-paclitaxel - TNBC | Phase 1 / Phase 2 | Active not recruiting | Biotheus Inc. | 42 | 2022-07-01 | 2025-03-11 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
Colorectal Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Gallbladder Neoplasms (1)
Digestive System Diseases (4) · Digestive System Neoplasms (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Male Urogenital Diseases (4) · Neoplasms by Site (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Breast Diseases (3) · Colonic Diseases (3) · Genital Diseases (3)
130-nm albumin-bound paclitaxel (2) · pembrolizumab (2) · Bevacizumab (1) · Docetaxel (1) · Irinotecan (1) · Platinum (1) · atezolizumab (1)
A2 Biotherapeutics Inc. (1) · Biotheus Inc. (1) · Genentech, Inc. (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · PMV Pharmaceuticals, Inc (1)
United States (3) · Australia (2) · China (2) · South Korea (2) · Spain (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Netherlands (1) · Singapore (1) · Taiwan (1) · United Kingdom (1)
John Welch, MD, PhD (1) · Marc Fellous, MD (1) · Wu Jiong (1)
PMID 40543428, PMID 40932470, PMID 41740031
2023 (1)